Analysis of the effects of androgens and training on myostatin propeptide and follistatin concentrations in blood and skeletal muscle using highly sensitive Immuno PCR

Molecular and Cellular Endocrinology

Volumn 330, Issue 1-2, 2010, Pages 1-9

  Diel, Patrick ^a   Schiffer, Thorsten ^a   Geisler, Stephan ^a   Hertrampf, Torsten ^a   Mosler, Stephanie ^a   Schulz, Sven ^a   Wintgens, Karl Florian ^c   Adler, Michael ^b  

^a GERMAN SPORT UNIVERSITY COLOGNE   (Germany)

^b CHIMERA BIOTEC GMBH   (Germany)

^c IMMUNDIAGNOSTIK AG   (Germany)

Author keywords

Androgens; Doping; Follistatin; Immuno PCR; Myostatin; Myostatin inhibitor; Myostatin propeptide

Indexed keywords

ANDROGEN; FOLLISTATIN; MYOSTATIN; TESTOSTERONE;

ADULT; ANIMAL EXPERIMENT; ARTICLE; ATHLETE; BLOOD SAMPLING; BODY BUILDING; CONTROLLED STUDY; DOPING; ENDURANCE TRAINING; ENZYME LINKED IMMUNOSORBENT ASSAY; FITNESS; GASTROCNEMIUS MUSCLE; HUMAN; HUMAN TISSUE; IMMUNOASSAY; MALE; MUSCLE BIOPSY; NONHUMAN; NORMAL HUMAN; ORCHIECTOMY; PHYSICAL ACTIVITY; POLYMERASE CHAIN REACTION; PRIORITY JOURNAL; PROTEIN BLOOD LEVEL; PROTEIN EXPRESSION; QUADRIPLEGIA; RAT; SENSITIVITY ANALYSIS; SKELETAL MUSCLE; WESTERN BLOTTING;

ANDROGENS; ANIMALS; BIOPSY; BLOTTING, WESTERN; FOLLISTATIN; HUMANS; MALE; MUSCLE, SKELETAL; MYOSTATIN; ORCHIECTOMY; ORGAN SIZE; PHYSICAL CONDITIONING, ANIMAL; PHYSICAL EDUCATION AND TRAINING; POLYMERASE CHAIN REACTION; PROTEIN PRECURSORS; RATS; RATS, WISTAR; TESTOSTERONE; YOUNG ADULT;

EID: 77957680808     PISSN: 03037207     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.mce.2010.08.015     Document Type: Article

References (30)

1. Adler M., Wacker R., Niemeyer C.M. A real-time immuno-PCR assay for routine ultrasensitive quantification of proteins. Biochem. Biophys. Res. Commun. 2003, 308:240-250.
2. Adler M., Langer M., Witthohn K., Wilhelm-Ogunbiyi K., Schöffski P., Fumoleau P., Niemeyer C.M. Adaptation and performance of an immuno-PCR assay for the quantification of aviscumine in patient plasma samples. J. Pharm. Biomed. Anal. 2005, 39:972-982.
3. Amthor H., Otto A., Vulin A., Rochat A., Dumonceaux J., Garcia L., Mouisel E., Hourdé C., Macharia R., Friedrichs M., Relaix F., Zammit P.S., Matsakas A., Patel K., Partridge T. Muscle hypertrophy driven by myostatin blockade does not require stem/precursor-cell activity. Proc. Natl. Acad. Sci. U.S.A. 2009, 106:7479-7484.
4. Bell D.R., Padua D.A., Clark M.A. Muscle strength and flexibility characteristics of people displaying excessive medial knee displacement. Arch. Phys. Med. Rehabil. 2008, 89:1323-1328.
5. Bogdanovich S., Krag T.O., Barton E.R., Morris L.D., Whittemore L.A., Ahima R.S., Khurana T.S. Functional improvement of dystrophic muscle by myostatin blockade. Nature 2002, 420:418-442.
6. Bogdanovich S., Perkins K.J., Krag T.O., Whittemore L.A., Khurana T.S. Myostatin propeptide-mediated amelioration of dystrophic pathophysiology. FASEB 2005, 19:543-549.
7. 2C12 myoblastoma cell differentiation and proliferation is stimulated by androgens and associated with a modulation of myostatin and Pax7 expression. Mol. Cell. Endocrinol. 2008, 291:1004-1010.
8. Diel P., Friedel A., Geyer H., Kamber M., Laudenbach-Leschowsky U., Schänzer W., Schleipen B., Thevis M., Vollmer G., Zierau O. The prohormone, 19-norandrostenedione displays selective androgen receptor modulator (SARM) like properties after subcutaneous administration. Toxicol. Lett. 2008, 177:198-204.
9. Furalyov V.A., Kravchenko I.V., Khotchenkov V.P., Popov V.O. siRNAs targeting mouse myostatin. Biochemistry 2008, 73:342-345.
10. Grobet L., Martin L.J., Poncelet D., Pirottin D., Brouwers B., Riquet J., Schoeberlein A., Dunner S., Ménissier F., Massabanda J., Fries R., Hanset R., Georges M., deletion in the A., 23 Jensky N.E., Sims J.K., Rice J.C., Dreyer H.C., Schroeder E.T. The influence of eccentric exercise on mRNA expression of skeletal muscle regulators. Eur. J. Appl. Physiol. 1997, 101:473-480.
11. Haidet A.M., Rizo L., Handy C., Umapathi P., Eagle A., Shilling C., Boue D., Martin P.T., Sahenk Z., Mendell J.R., Kaspar B.K. Long-term enhancement of skeletal muscle mass and strength by single gene administration of myostatin inhibitors. Proc. Natl. Acad. Sci. U.S.A. 2008, 105:4318-4322.
12. Hill J.J., Davies M.V., Pearson A.A., Wang J.H., Hewick R.M., Wolfman N.M., Qiu Y. The myostatin propeptide and the follistatin-related gene are inhibitory binding proteins of myostatin in normal serum. J. Biol. Chem. 2002, 277:40735-40741.
13. Huet C., Li Z.F., Liu H.Z., Black R.A., Galliano M.F., Engvall E. Skeletal muscle cell hypertrophy induced by inhibitors of metalloproteases; myostatin as a potential mediator. Am. J. Physiol. Cell Physiol. 2001, 281:C1624-1634.
14. Hulmi J.J., Tannerstedt J., Selänne H., Kainulainen H., Kovanen V., Mero A. Resistance exercise with whey protein ingestion affects mTOR signalling pathway and myostatin in men. J. Appl. Physiol. 2009, 106:1720-1729.
15. Jensky N.E., Sims J.K., Rice J.C., Dreyer H.C., Schroeder E.T. The influence of eccentric exercise on mRNA expression of skeletal muscle regulators. Eur. J. Appl. Physiol. 2007, 101:473-480.
16. Khurana T.S., Davies K.E. Pharmacological strategies for muscular dystrophy. Nat. Rev. Drug Discov. 2003, 2:379-390.
17. Kim J., Petrella J., Cross J., Bamman M. Load mediated downregulation of myostatin mRNA is not sufficient to promot myofiber hypertrophy in humans, a cluster analysis. J. Appl. Physiol. 2007, 106:1488-1495.
18. Lakshman K.M., Bhasin S., Corcoran C., Collins-Racie L., Tchitiakova L.A., Forlow S., Ledger K., Burczynski M., Dorner a, Lavallie E. Measurement of myostatin concentrations in human serum: circulating concentrations in young and older men and effects of testosterone administration. Mol. Cell. Endocrinol. 2009, 302:26-32.
19. Lee S.J., McPherron A.C. Regulation of myostatin activity and muscle growth. Proc. Natl. Acad. Sci. U.S.A. 2001, 98:9306-9311.
20. Liu C.M., Yang Z., Liu C.W., Tien P., Dale R., Sun L. Myostatin antisense RNA-mediated muscle growth in normal and cancer cachexia mice. Gene Ther. 2008, 15:155-160.
21. McPherron A.C., Lawler A.M., Lee S.J. Regulation of skeletal muscle mass in mice by a new TGF-beta superfamily member. Nature 1997, 387:83-90.
22. McPherron A.C., Lee S.J. Suppression of body fat accumulation in myostatin-deficient mice. J. Clin. Invest. 2002, 109:595-601.
23. Niemeyer C.M., Adler M., Wacker R. Immuno-PCR: high sensitivity detection of proteins by nucleic acid amplification. Trends Biotechnol. 2005, 23:208-216.
24. Rae K., Hollebone K., Chetty V., Clausen D., McFarlane J. Follistatin serum concentrations during full-term labour in women-significant differences between spontaneous and induced labour. Reproduction 2007, 134:705-711.
25. Reis F.M., Nascimento L.L., Tsigkou A., Ferreira M.C., Luisi S., Petraglia F. Activin A and follistatin in menstrual blood: low concentrations in women with dysfunctional uterine bleeding. Reprod. Sci. 2007, 14:383-389.
26. Schuelke M., Wagner K.R., Stolz L.E., Hübner C., Riebel T., Kömen W., Braun T., Tobin J.F., Lee S.J. Myostatin mutation associated with gross muscle hypertrophy in a child. N. Engl. J. Med. 2004, 350:2682-2688.
27. Thies R.S., Chen T., Davies M.V., Tomkinson K.N., Pearson A.A., Shakey Q.A., Wolfman N.M. GDF-8 propeptide binds to GDF-8 and antagonizes biological activity by inhibiting GDF-8 receptor binding. Growth Factors 2001, 18:251-259.
28. Wagner K.R., Fleckenstein J.L., Amato A.A., Barohn R.J., Bushby K., Escolar D.M., Flanigan K.M., Pestronk A., Tawil R., Wolfe G.I., Eagle M., Florence J.M., King W.M., Pandya S., Straub V., Juneau P., Meyers K., Csimma C., Araujo T., Allen R., Parsons S.A., Wozney J.M., Lavallie E.R., Mendell J.R. A phase I/II trial of MYO-029 in adult subjects with muscular dystrophy. Ann. Neurol. 2008, 63:561-566.
29. Whittemore L.A., Song K., Li X., Aghajanian J., Davies M., Girgenrath S., Hill J.J., Jalenak M., Kelley P., Knight A., Maylor R., O'Hara D., Pearson A., Quazi A., Ryerson S., Tan X.Y., Tomkinson K.N., Veldman G.M., Widom A., Wright J.F., Wudyka S., Zhao L., Wolfman N.M. Inhibition of myostatin in adult mice increases skeletal muscle mass and strength. Biochem. Biophys. Res. Commun. 2003, 300:965-967.
30. Yamasaki K., Sawaki M., Ohta R., Okuda H., Katayama S., Yamada T., Ohta T., Kosaka T., Owens W. OECD validation of the Hershberger assay in Japan: phase 2 dose response of methyltestosterone, vinclozolin, and p,p'-DDE. Environ. Health Perspect. 2003, 111:1912-1919.